This article is more than 5 years old. Information may no longer be current.

Glaukos establishes direct sales organization, launches iStent inject in Australia

Issue: February 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Glaukos has established a direct sales organization and launched the iStent inject trabecular micro-bypass stent in Australia, according to a press release.

The iStent inject was approved by the Therapeutic Goods Administration. It is to be used with cataract surgery to reduce IOP in patients with mild to moderate glaucoma who are being treated with ocular hypotensive medication.

“Our investment in Australia demonstrates our continued commitment to expand our direct sales operations in targeted markets and increase the global reach of our breakthrough iStent technology platform,” Thomas Burns, president and CEO of Glaukos, said in the release.